Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pertuzumab”

272 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 272 results

Testing effectiveness (Phase 2)Study completedNCT01796197
What this trial is testing

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 23
Testing effectiveness (Phase 2)Study completedNCT00951665
What this trial is testing

Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 107
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07545044
What this trial is testing

JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc. 60
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Not applicableUnknownNCT02101879
What this trial is testing

Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes

Who this might be right for
Cardiotoxicity.Anti Her2 Therapy.Metastatic Breast Cancer
Rambam Health Care Campus 20
Early research (Phase 1)Study completedNCT02490475
What this trial is testing

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Who this might be right for
Solid Tumor
Hoffmann-La Roche 19
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Large-scale testing (Phase 3)Study completedNCT04024462
What this trial is testing

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Hoffmann-La Roche 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT06136897
What this trial is testing

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Large-scale testing (Phase 3)Looking for participantsNCT05256225
What this trial is testing

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Who this might be right for
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI) 360
Large-scale testing (Phase 3)Active Not RecruitingNCT06057610
What this trial is testing

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 868
Early research (Phase 1)Study completedNCT02494596
What this trial is testing

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Hoffmann-La Roche 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07246317
What this trial is testing

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 188
Testing effectiveness (Phase 2)Study completedNCT02132949
What this trial is testing

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 401
Testing effectiveness (Phase 2)UnknownNCT05749016
What this trial is testing

Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer

Who this might be right for
Locally Advanced Breast CancerChemotherapy Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Large-scale testing (Phase 3)Looking for participantsNCT05159193
What this trial is testing

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 372
Testing effectiveness (Phase 2)Ended earlyNCT04578106
What this trial is testing

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast CancerStage I Breast Cancer
Fundacio Clinic Barcelona 5
Testing effectiveness (Phase 2)Study completedNCT00301899
What this trial is testing

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Who this might be right for
Breast Cancer
National Institutes of Health Clinical Center (CC) 37
Testing effectiveness (Phase 2)Study completedNCT02339532
What this trial is testing

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Who this might be right for
Breast Cancer
UNICANCER 86
Testing effectiveness (Phase 2)Study completedNCT00096941
What this trial is testing

Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Who this might be right for
Solid Cancers
Genentech, Inc. 3
Next Page